Clinical Trial Update: NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating NT-I7 (efineptakin alfa) in combination with pembrolizumab in adults with advanced solid tumors has completed and results have been p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Pancreatic Cancer
• Small Cell Lung Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• NT-I7
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: NeoImmuneTech | Conditions: Any Advanced Solid Tumors, Triple Negative Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2026-02-09